Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer

Krzyzanowska, Agnieszka LU ; Higgins, Debra F. ; Barron, Stephen ; Loughman, Tony ; O'Neill, Amanda ; Sheehan, Katherine M. ; Wang, Chan Ju Angel ; Fender, Bozena ; McGuire, Leah and Fay, Joanna , et al. (2024) In BJUI Compass
Abstract

Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T-stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C-indexes from Cox proportional hazard regression models. Results: Biopsy MCRS was... (More)

Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T-stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C-indexes from Cox proportional hazard regression models. Results: Biopsy MCRS was significantly prognostic (p < 0.0001) and added significant prognostic value to clinico-pathological features for adverse pathology, high primary Gleason and high pathological T-stage (p < 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non-significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort. Conclusion: Biopsy-based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
gene expression signature, molecular risk score, patient management, prognosis, prostate cancer, risk stratification, treatment decisions
in
BJUI Compass
publisher
John Wiley & Sons Inc.
external identifiers
  • pmid:39877562
  • scopus:85211579556
DOI
10.1002/bco2.474
language
English
LU publication?
yes
id
7f93b097-78ea-453d-a89e-7778f057b8df
date added to LUP
2025-01-30 12:45:39
date last changed
2025-07-04 01:42:34
@article{7f93b097-78ea-453d-a89e-7778f057b8df,
  abstract     = {{<p>Objectives: This study aimed to clinically validate the six-gene prognostic molecular clinical risk score (MCRS) for the prediction of aggressive prostate cancer in diagnostic biopsy tissue. Methods: MCRS was evaluated in prostate biopsy tissue from a Swedish cohort of men with prostate cancer (UPCA, n = 100). The primary outcome of adverse pathology and secondary outcomes of high primary Gleason (≥G4) and high pathological T-stage (≥T3) were assessed by likelihood ratio statistics and area under the receiver operating characteristic curves from logistic regression models; time to biochemical recurrence was assessed by likelihood ratio statistics and C-indexes from Cox proportional hazard regression models. Results: Biopsy MCRS was significantly prognostic (p &lt; 0.0001) and added significant prognostic value to clinico-pathological features for adverse pathology, high primary Gleason and high pathological T-stage (p &lt; 0.0001). MCRS was prognostic for biochemical recurrence and added some, albeit non-significant, prognostic value to clinical risk stratifiers, which could reflect the low number of recurrence events in the cohort. Conclusion: Biopsy-based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.</p>}},
  author       = {{Krzyzanowska, Agnieszka and Higgins, Debra F. and Barron, Stephen and Loughman, Tony and O'Neill, Amanda and Sheehan, Katherine M. and Wang, Chan Ju Angel and Fender, Bozena and McGuire, Leah and Fay, Joanna and O'Grady, Anthony and O'Leary, Des and Watson, R. William and Bjartell, Anders and Gallagher, William M.}},
  keywords     = {{gene expression signature; molecular risk score; patient management; prognosis; prostate cancer; risk stratification; treatment decisions}},
  language     = {{eng}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{BJUI Compass}},
  title        = {{Clinical validation of a biopsy-based six-gene signature prognostic for aggressive prostate cancer}},
  url          = {{http://dx.doi.org/10.1002/bco2.474}},
  doi          = {{10.1002/bco2.474}},
  year         = {{2024}},
}